Survival Improvment With Sacituzumab Govitecan in HR+/HER2– mBC

Frederick Marme, MD, discusses new results from the TROPICS-02 study of sacituzumab govitecan for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Frederik Marme, PhD, head professor at Heidelberg, Baden Wurttemberg, discusses new results from the TROPICS-02 study of sacituzumab govitecan (Trodelvy) for the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

The findings were presented by Marme during the European Society of Medical Oncology Annual Meeting 2022.

Transcript:

0:07 | This was now actually demonstrating statistically significant and clinically meaningful improvement in overall survival with a reduction of the risk of death by 21%. That's really reassuring. You have to bear in mind that the population of patients that were treated in TROPICS-02 is heavily pretreated. So, the median number of lines of chemotherapy for metastatic disease was 3, and the time from the diagnosis of metastases to the entry into the trial was 4 years. These patients have been treated with for metastatic breast cancer for 4 years, and everybody in this study did receive a prior CDK4/6 inhibitor, so it was a heavily pretreated resistant population. To see such a big overall advantage in this population is good news.

1:09 | We did also look into subgroups, for example stratified by HER2 immunohistochemistry. We found that in the patients were all HER2-low or HER2-negative but obviously HER2 is a new sub-population of HER2-negative patients that's of interest because there's targeted agents against her to in that setting.

1:32 | We did basically saw that sacituzumab govitecan does work, irrespective of HER2 [immunohistochemistry] status in the HER2-negative setting. On top of these great PFS and OS results, we've also presented the quality-of-life results. And it's very nice to see also that sacituzumab govitecan significantly improved the time to deterioration of quality of life and in the global quality of life scores, as well as fatigue versus treatment of physician’s choice. So, it does lead to responses, it does add overall survival benefit, but it does not deteriorate quality of life. And by having a prolonged response to therapy, the patients are able to maintain their quality of life.